Neurana Pharmaceuticals Inc., a US-based, privately held, clinical-stage, biotechnology company, announced on Monday that it has completed the enrolment of 1,000 patients for the Phase three RESUME-1 Study of tolperisone intended for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.
The company expects to report topline data in the first quarter of 2022.
Neurana introduced the phase three RESUME-1 Study in December 2020. The double-blind, randomised, placebo controlled clinical trial was intended to evaluate the safety and efficiency of tolperisone for the relief of muscle spasm associated with acute, painful musculoskeletal conditions in 1,000 patients. The study randomised the patients equally to receive placebo or tolperisone 50mg, 100mg, or 200mg administered three times per day for 14 days.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval